Total Payments
$55,896
2024 Payments
$49,998
Companies
33
Transactions
177
Medicare Patients
448
Medicare Billing
$121,880
Payment Breakdown by Category
Research$50,414 (90.2%)
Food & Beverage$3,765 (6.7%)
Travel$1,716 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $50,414 | 3 | 90.2% |
| Food and Beverage | $3,765 | 169 | 6.7% |
| Travel and Lodging | $1,716 | 5 | 3.1% |
Payments by Type
Research
$50,414
3 transactions
General
$5,481
174 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $49,599 | 1 | $0 (2024) |
| Biogen, Inc. | $2,085 | 10 | $0 (2023) |
| Indivior Inc. | $908.22 | 30 | $0 (2024) |
| West-Ward Pharmaceuticals | $815.38 | 2 | $0 (2018) |
| Scilex Pharmaceuticals Inc. | $399.17 | 23 | $0 (2023) |
| Braeburn Inc. | $225.68 | 8 | $0 (2024) |
| Horizon Therapeutics plc | $224.15 | 14 | $0 (2022) |
| Arbor Pharmaceuticals, Inc. | $207.19 | 11 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $202.16 | 13 | $0 (2022) |
| GRT US Holding, Inc. | $140.59 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,998 | 17 | Eli Lilly and Company ($49,599) |
| 2023 | $2,531 | 30 | Biogen, Inc. ($2,085) |
| 2022 | $555.18 | 25 | Indivior Inc. ($132.58) |
| 2021 | $709.56 | 35 | Horizon Therapeutics plc ($174.97) |
| 2020 | $306.70 | 15 | Arbor Pharmaceuticals, Inc. ($66.37) |
| 2019 | $402.17 | 23 | Scilex Pharmaceuticals Inc. ($152.80) |
| 2018 | $1,154 | 17 | West-Ward Pharmaceuticals ($815.38) |
| 2017 | $238.63 | 15 | Merck Sharp & Dohme Corporation ($67.38) |
All Payment Transactions
177 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $34.84 | General |
| Category: OUD | ||||||
| 11/06/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $8.87 | General |
| Category: OUD | ||||||
| 10/24/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: OUD | ||||||
| 09/16/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $49,599.00 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | ||||||
| 08/28/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $35.45 | General |
| Category: OUD | ||||||
| 08/12/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: Opioid Use Disorder | ||||||
| 07/11/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $32.05 | General |
| Category: OUD | ||||||
| 06/21/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 05/17/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: OUD | ||||||
| 04/26/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: OUD | ||||||
| 04/24/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $9.31 | General |
| Category: OUD | ||||||
| 03/14/2024 | Curonix LLC | PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A (Device) | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: PAIN MANAGEMENT | ||||||
| 02/27/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: Opioid Use Disorder | ||||||
| 02/26/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $28.63 | General |
| Category: OUD | ||||||
| 01/31/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $29.30 | General |
| Category: Opioid Use Disorder | ||||||
| 01/22/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: OUD | ||||||
| 01/12/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $30.22 | General |
| Category: Opioid Use Disorder | ||||||
| 12/19/2023 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $29.86 | General |
| Category: Opioid Use Disorder | ||||||
| 12/12/2023 | Azurity Pharmaceuticals, Inc. | Horizant (Drug) | Food and Beverage | Cash or cash equivalent | $15.87 | General |
| Category: Sleep | ||||||
| 12/11/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $29.42 | General |
| Category: OUD | ||||||
| 12/01/2023 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $29.98 | General |
| Category: Opioid Use Disorder | ||||||
| 10/27/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: OUD | ||||||
| 10/26/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Analgesic | ||||||
| 10/24/2023 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $27.19 | General |
| Category: Opioid Use Disorder | ||||||
| 10/13/2023 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $342.84 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | Eli Lilly and Company | $49,599 | 1 |
| Opioid PMR Study | West-Ward Pharmaceuticals | $815.38 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 77 | 254 | $68,500 | $18,955 |
| 2022 | 4 | 122 | 373 | $103,275 | $29,056 |
| 2021 | 3 | 108 | 317 | $91,125 | $29,447 |
| 2020 | 4 | 141 | 538 | $164,150 | $44,422 |
Total Patients
448
Total Services
1,482
Medicare Billing
$121,880
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 160 | $36,000 | $9,677 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 81 | $26,325 | $7,528 | 28.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $6,175 | $1,751 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 186 | $60,450 | $18,038 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 106 | $23,850 | $6,610 | 27.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $13,775 | $3,995 | 29.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 11 | 52 | $5,200 | $412.95 | 7.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 41 | 123 | $39,975 | $13,059 | 32.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 37 | 164 | $36,900 | $12,304 | 33.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 30 | 30 | $14,250 | $4,084 | 28.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 46 | 289 | $92,425 | $24,242 | 26.2% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 34 | 84 | $29,875 | $8,796 | 29.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 38 | 142 | $31,550 | $8,292 | 26.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 23 | 23 | $10,300 | $3,091 | 30.0% |
About Dr. James Lai, M.D
Dr. James Lai, M.D is a Pain Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/03/2005. The National Provider Identifier (NPI) number assigned to this provider is 1942291406.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Lai, M.D has received a total of $55,896 in payments from pharmaceutical and medical device companies, with $49,998 received in 2024. These payments were reported across 177 transactions from 33 companies. The most common payment nature is "" ($50,414).
As a Medicare-enrolled provider, Lai has provided services to 448 Medicare beneficiaries, totaling 1,482 services with total Medicare billing of $121,880. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Other Specialties Pain Medicine, Addiction Medicine
- Location Houston, TX
- Active Since 11/03/2005
- Last Updated 03/19/2018
- Taxonomy Code 2081P2900X
- Entity Type Individual
- NPI Number 1942291406
Products in Payments
- SUBLOCADE (Drug) $908.22
- Oxycodone hydrochloride ER tablet (Drug) $815.38
- Horizant (Drug) $241.08
- BRIXADI (Drug) $225.68
- ZTLido (Drug) $202.46
- RELISTOR (Drug) $202.16
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $170.04
- Qutenza (Drug) $140.59
- PENNSAID (Drug) $120.24
- DUEXIS (Drug) $98.68
- BELSOMRA (Drug) $93.61
- AIMOVIG (Biological) $87.57
- GRALISE (Drug) $80.88
- VIVITROL (Drug) $78.79
- Gralise (Drug) $64.52
- Movantik (Drug) $61.73
- Zipsor (Drug) $50.78
- QULIPTA (Drug) $44.75
- Nucynta (Drug) $41.57
- Vivitrol (Drug) $38.04
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pain Medicine Doctors in Houston
Robert Sickler, Md, MD
Pain Medicine — Payments: $143,646
Pain Medicine $143,646
Michael Sprintz, Do, DO
Pain Medicine — Payments: $65,205
Pain Medicine $65,205
Dr. Mayur Kanjia, M.d, M.D
Pain Medicine — Payments: $50,110
Pain Medicine $50,110
Wai-Kwan Yung, M.d, M.D
Pain Medicine — Payments: $40,975
Pain Medicine $40,975
Mitchell Engle, M.d., Ph.d, M.D., PH.D
Pain Medicine — Payments: $39,934
Pain Medicine $39,934
Dr. Thuan Dao, Md, MD
Pain Medicine — Payments: $25,655
Pain Medicine $25,655